Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.

about

Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.

Item

http://www.wikidata.org/entity/Q41708707

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Positive transcription elongat ...... get in human multiple myeloma.

@en

type

Item

label

Positive transcription elongat ...... get in human multiple myeloma.

@en

prefLabel

Positive transcription elongat ...... get in human multiple myeloma.

@en

P1476

Positive transcription elongat ...... get in human multiple myeloma.

@en

P2093

Liang Zhou

http://www.w3.org/2001/XMLSchema#string

Steven Grant

http://www.w3.org/2001/XMLSchema#string

Yu Zhang

http://www.w3.org/2001/XMLSchema#string

Yun Dai

http://www.w3.org/2001/XMLSchema#string

Yun Leng

http://www.w3.org/2001/XMLSchema#string

P2860

MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

New investigational drugs with single-agent activity in multiple myeloma

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

Genome-scale CRISPR-Cas9 knockout screening in human cells

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.

P304

59476-59491

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19761

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robert Z Orlowski

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28938651

http://www.w3.org/2001/XMLSchema#string

P932

5601747

http://www.w3.org/2001/XMLSchema#string